Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ADAKVEO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ADAKVEO
Date registered
Evaluation commenced
Decision date
Approval time
215 (255 working days)
Active ingredients
crizanlizumab
Registration type
NCE/NBE
Indication
ADAKVEO (concentrate solution for infusion) is indicated for the prevention of recurrent vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.